Press release
Europe mRNA Vaccine Market to Reach USD 43.2 Billion by 2031 Driven by Advances in Preventive Healthcare
Europe mRNA Vaccine Market
The market expansion is supported by increasing government funding for pandemic preparedness, accelerated immunization initiatives, and rising prevalence of infectious diseases. Continuous improvements in RNA synthesis, encapsulation technologies, and lipid nanoparticle (LNP) delivery systems are enhancing vaccine effectiveness and production efficiency. Europe's ongoing commitment to personalized and precision medicine is further boosting the adoption of mRNA vaccines across both prophylactic and therapeutic segments.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/mrna-vaccines-market---pipeline-insights?utm_source=OpenPR&utm_campaign=Onkar
Key Highlights from the Report
➤ The Europe mRNA Vaccine Market will reach USD 43.2 billion by 2031, growing at 21.1% CAGR.
➤ Strong government funding and public-private partnerships underpin Europe's leadership in mRNA innovation.
➤ Oncology and rare disease applications are emerging as major growth segments beyond infectious diseases.
➤ Lipid nanoparticle (LNP) delivery systems are evolving rapidly, improving vaccine stability and immunogenicity.
➤ Multivalent and combination mRNA vaccines for influenza, RSV, and COVID-19 are in advanced development stages.
➤ Europe's top biotech hubs, including Germany, France, and the U.K., drive vaccine R&D and commercialization.
Market Segmentation
By application, the market divides into infectious disease prevention and therapeutic vaccines. The infectious disease segment continues to dominate, propelled by large-scale adoption of COVID-19 and influenza mRNA vaccines. However, the oncology segment is anticipated to grow fastest, as companies advance personalized cancer immunotherapies that train the immune system to detect tumor-specific antigens.
By technology, mRNA platforms are segmented into conventional mRNA, self-amplifying mRNA (saRNA), and circular RNA (circRNA). Self-amplifying and circular formats demonstrate longer immunological durability and reduced dosage requirements, spurring pharmaceutical interest. Advanced encapsulation carriers, including polymer-based and peptide-based delivery systems, complement existing lipid nanoparticle formulations to boost efficacy and safety.
By end user, demand is categorized across pharmaceutical companies, research institutions, and healthcare providers. Pharmaceutical corporations dominate market share due to their high R&D spending, expansive manufacturing infrastructure, and strategic alliances with regulatory bodies and academic research centers.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/mrna-vaccines-market---pipeline-insights?utm_source=OpenPR&utm_campaign=Onkar
Regional Insights
Europe remains at the forefront of global vaccine innovation, anchored by strong governmental initiatives and private investments in biotechnology.
Germany leads the regional market, home to breakthrough mRNA innovators such as BioNTech SE and CureVac AG, supported by extensive domestic funding and strong export activity. The country's focus on scaling vaccine production and fostering strategic partnerships ensures a sustained leadership position.
The United Kingdom continues to expand its mRNA vaccine R&D infrastructure post-Brexit, emphasizing clinical trials for cancer and chronic illness therapies. France, Spain, and Italy follow closely, strengthening vaccine manufacturing supply chains through collaborations with research organizations and public health institutes.
Across Eastern Europe, nations like Poland and Hungary are witnessing rising investments in mRNA vaccine packaging and production facilities, encouraged by EU health security grants aimed at pandemic readiness.
Market Dynamics
Market Drivers
The unprecedented success of mRNA vaccines during the COVID-19 pandemic validated their rapid development potential and global scalability. This proof of concept has expanded R&D pipelines beyond infection control toward chronic and lifestyle-related diseases. Rising prevalence of influenza, RSV, and emerging zoonotic infections, coupled with personalized medicine initiatives, continues to energize regional growth.
Market Restraints
Complex production requirements for RNA synthesis and encapsulation pose logistical and cost challenges. Limited availability of key raw materials and skilled personnel necessary for advanced biotech manufacturing constrains expansion. High development costs and stringent regulations also delay market entry for smaller biotech players.
Market Opportunities
Europe's strong regulatory framework and clinical research capabilities create massive potential for next-generation mRNA platforms, including combination vaccines and cancer therapeutics. Continuous innovation in thermostable formulations promises improved distribution across resource-limited areas. Expanding institutional support and R&D partnerships will ensure sustainable commercialization and greater vaccine accessibility.
Purchase This Exclusive Report at Just USD 6231 Only: https://www.datamintelligence.com/buy-now-page?report=mrna-vaccines-market---pipeline-insights?utm_source=OpenPR&utm_campaign=Onkar
Reasons to Buy the Report
✔ Identification of technological innovations driving Europe's mRNA vaccine growth trajectory.
✔ Regional insights into key economies spearheading marketplace investments and regulations.
✔ Comprehensive segmentation across prophylactic and therapeutic applications.
✔ Evaluation of strategic collaborations fostering biotech innovation in Europe.
✔ Reliable industry forecasts and verified data by DataM Intelligence.
Frequently Asked Questions (FAQs)
◆ How large will the Europe mRNA Vaccine Market be by 2031?
◆ Which therapeutic areas are driving new vaccine developments in Europe?
◆ What technological advancements are shaping mRNA production and delivery?
◆ Who are the key players leading the Europe mRNA Vaccine Market?
◆ How are European governments supporting domestic mRNA manufacturing?
Company Insights
BioNTech SE (Germany)
Moderna Inc. (U.S.)
CureVac AG (Germany)
Sanofi S.A. (France)
GlaxoSmithKline Plc (U.K.)
Pfizer Inc. (U.S.)
Arcturus Therapeutics Holdings Inc. (U.S.)
Translate Bio (U.S.)
Ethris GmbH (Germany)
Alnylam Pharmaceuticals Inc. (U.S.)
Recent Developments:
May 2025: BioNTech expanded its R&D pipeline with Phase II trials for personalized melanoma mRNA vaccines in Germany and Italy.
March 2025: CureVac AG completed safety validation for its multivalent mRNA influenza and RSV vaccine candidate under the EU Horizon health initiative.
Conclusion
The Europe mRNA Vaccine Market is poised for exceptional growth, emerging as a cornerstone of modern immunization and personalized medicine. With strong public-private investment, advanced lipid nanoparticle delivery systems, and diversified applications beyond infectious diseases, mRNA vaccines are redefining Europe's healthcare and biotechnology landscape. From combating pandemics to enabling individualized cancer therapies, the region's scientific progress ensures steady transformation toward faster, safer, and scalable vaccine production capabilities. By 2031, Europe stands positioned as a global innovation hub for next-generation mRNA therapeutics.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Europe mRNA Vaccine Market to Reach USD 43.2 Billion by 2031 Driven by Advances in Preventive Healthcare here
News-ID: 4225311 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Smart Classroom Market Set to Grow at 17.4% CAGR Driven by Digital Learning | To …
Global Smart Classroom Market is expected to reach at a CAGR of 17.4% within the forecast period (2024-2031).
According to DataM Intelligence has published a new research report on "Smart Classroom Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of…
Revenue Cycle Management Market to Reach US$ 291.19 Billion by 2033 at 12.4% CAG …
The global revenue cycle management market size reached US$ 102.16 billion in 2024 is expected to reach US$ 291.19 billion by 2033, growing at a CAGR of 12.4% during the forecast period 2025-2033.
According to DataM Intelligence has published a new research report on "Revenue Cycle Management Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top…
IT Asset Management Software Market to Reach US$ 4.14 Billion by 2033 at 7.11% C …
The global IT asset management software market reached US$ 2,132.33 million in 2023, with a rise to US$ 2,255.49 million in 2024, and is expected to reach US$ 4,139.20 million by 2033, growing at a CAGR of 7.11% during the forecast period 2025-2033.
According to DataM Intelligence has published a new research report on "IT Asset Management Software Market Size 2025". The report explores comprehensive and insightful Information about various…
Debt Collection Software Market Trends: Predictive Analytics, Cloud, and Omnicha …
Debt Collection Software Market is growing at a CAGR of 9.9 % in the forecast period (2024-2031)
According to DataM Intelligence has published a new research report on "Debt Collection Software Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
